Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Abstract

To measure the evolution of the serum levels of specific Osteoarthritis (OA) biomarker, Coll2-1 and Coll2-1 NO 2 in knee osteoarthritic patients after viscosupplementation (VS). Fifty-one patients with unilateral symptomatic knee were recruited for this prospective open label study. They received three intra-articular injections of 2 ml of hyaluronic acid (Hylan GF-20) and were followed for 3 months. Walking pain was evaluated and serum samples were taken at each visit. Coll2-1 and Coll2-1 NO 2 were measured in the serum using specific immunoassays. Variations over time of each parameter and predictive factor of response were studied. Forty-five patients were analyzed. The serum concentrations of Coll2-1 and Coll2-1 NO 2 were significantly higher in KL III/IV patients compared to KL I/II patients at baseline and decreased systematically over time after VS. Its effect was ever more pronounced in patients with KL III/IV. The serum concentration of Coll2-1 was significantly lower at baseline in responders than in non-responders. This study suggests a rapid slowdown of type II collagen degradation and joint inflammation after VS with Hylan G-20 and gives additional information for the validation of accurate biomarkers for OA. The serum level of Coll2-1 appeared to be a predictive factor for response to treatment. ß

Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial

“…HA injections in a previous study including 45 patients produced a decrease in Coll2-1 superior to 10 nmol/l in 48% of the patient [20]. The hypothesis was made that Kartilage® Cross treatment in this study will produce a decrease of 10 nmol/l of Coll2-1 between inclusion and D90 in the serum in 45% of the patients.…”

“…When measured in serum of patients with OA it was found to be in higher concentrations than age-matched controls [18]. Interestingly, Coll2-1 has been shown to be decrease in serum of patients with knee OA after a series of 3 injections of hylan GF-20, suggesting that this biomarker could be helpful for the monitoring of IAHA effect [20]. Coll2-1 is a biomarker of OA that entered the qualification process [21].…”

“…In preclinical studies, Coll2-1 was qualified as biomarker of burden of disease as the increase of the concentration of the biomarker in serum correlated with the histological severity and the global macroscopic score [24, 25]. Finally, in human clinical trials, Coll2-1 was used to monitor the efficacy of intra-articular viscosupplementation [20] and joint health food supplement [26]. …”

Effects of low molecular weight hyaluronan combined with carprofen on canine osteoarthritis articular chondrocytes and cartilage explants in vitro

“…Proteoglycan and type II collagen are degraded at the surface, leading to loss of structural strength of articular cartilage due to aggrecanase and matrix metalloproteinases (MMPs) (Struglics et al 2006) and decreased type II collagen and aggrecan integrity (Garnero et al 2002;Jalbă et al 2011;Henrotin et al 2013). Therefore, type II collagen and proteoglycan can be used as biochemical markers of early stage canine OA (Matyas et al 2004).…”

Addition of Mannitol to Hyaluronic Acid may Shorten Viscosupplementation Onset of Action in Patients with Knee Osteoarthritis: Post-Hoc Analysis of A Double-blind, Controlled Trial

“…The more probable hypothesis is a transient restoration of the physiological joint homeostasis [6]. Moreover there are increasing in vitro and in vivo evidences that HA could have chondroprotective properties [7][8][9][10][11][12] whereas metaanalyses continue to show controversial results regarding the efficacy and safety of viscosupplementation [13][14][15][16][17].…”